[Bioequivalence of pyridostigmine bromide dispersible tablets in rabbits].
OBJECTIVE
To compare the pharmacokinetic parameters of pyridostigmine bromide dispersible tablets and common tablets in rabbits.


METHODS
Twelve rabbits were given an oral dose (60 mg) of pyridostigmine bromide dispersible tablets or common tablets in a randomized crossover study. The plasma concentration of pyridostigmine bromide was determined by reversed-phase ion pair chromatography. The pharmacokinetic parameters were calculated using DAS2.1.1 software.


RESULTS
The pharmacokinetic parameters showed no significant differences in rabbit plasma between pyridostigmine bromide dispersible tablets and common tablets. The two tablets had a C(max) of 1.83∓0.08 mg·L(-1) and 1.68∓0.03 mg·L(-1), tmax of 2.33∓0.41 h and 2.58∓0.20 h, AUC(0-24) of 15.50∓0.62 mg·h·L(-1) and 15.14∓0.30 mg·h·L(-1), AUC(0-∞) of 15.82∓0.70 mg·h·L(-1) and 15.57∓0.32 mg·h·L(-1), respectively. The relative bioavailability F(0-24) was 102.38% and F(0-∞) was 101.61% for the dispersible tablets.


CONCLUSIONS
The two tablets are bioequivalent in rabbits.
Chongqing Medical University, Chongqing, China.
Hong
H
Wang
Hong
H
Wang
Qun-you
QY
Tan
Li
L
Zhang
Xun-guan
XG
Cheng
Jing-qing
JQ
Zhang
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D005260:Female; D008297:Male; D011729:Pyridostigmine Bromide / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics*; D011817:Rabbits; D013607:Tablets; D013810:Therapeutic Equivalency
D013607:Tablets; D011729:Pyridostigmine Bromide